NASDAQ:AXDXAccelerate Diagnostics Stock Price, Forecast & News

Accelerate Diagnostics' stock was trading at $10.61 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AXDX stock has decreased by 22.2% and is now trading at $8.25. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Accelerate Diagnostics.

Accelerate Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Accelerate Diagnostics.

Accelerate Diagnostics Inc (NASDAQ:AXDX) released its quarterly earnings data on Thursday, May, 7th. The medical research company reported ($0.39) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.39). The medical research company had revenue of $2.34 million for the quarter, compared to analyst estimates of $2.40 million. Accelerate Diagnostics had a negative return on equity of 5,681.44% and a negative net margin of 845.43%. View Accelerate Diagnostics' earnings history.

Accelerate Diagnostics updated its first quarter 2020 After-Hours earnings guidance on Wednesday, April, 15th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.3-2.3 million, compared to the consensus revenue estimate of $2.32 million.

3 equities research analysts have issued 12 month target prices for Accelerate Diagnostics' shares. Their forecasts range from $14.00 to $19.00. On average, they expect Accelerate Diagnostics' share price to reach $16.33 in the next twelve months. This suggests a possible upside of 98.0% from the stock's current price. View analysts' price targets for Accelerate Diagnostics.

Press coverage about AXDX stock has been trending very negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Accelerate Diagnostics earned a news impact score of -3.5 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutAccelerate Diagnostics.

Accelerate Diagnostics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 16,640,000 shares, an increase of 5.4% from the April 30th total of 15,780,000 shares. Based on an average daily trading volume, of 447,000 shares, the days-to-cover ratio is currently 37.2 days. Approximately 52.9% of the shares of the stock are sold short. View Accelerate Diagnostics' Current Options Chain.

Some companies that are related to Accelerate Diagnostics include Quanterix (QTRX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Aethlon Medical (AEMD), Scientific Industries (SCND), Precipio (PRPO), Arrayit (ARYC), Pressure Biosciences (PBIO), Horiba (HRIBF) and PositiveID (PSID). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AbbVie (ABBV), AT&T (T) and Exelixis (EXEL).

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Accelerate Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.64%), AXA (3.62%), Griffin Asset Management Inc. (2.52%), ArrowMark Colorado Holdings LLC (1.91%), Chicago Capital LLC (1.58%) and State Street Corp (1.09%). Company insiders that own Accelerate Diagnostics stock include Jack W Schuler, John Patience, Steven Reichling and Thomas D Brown. View institutional ownership trends for Accelerate Diagnostics.

AXDX stock was sold by a variety of institutional investors in the last quarter, including CSS LLC IL, Chicago Capital LLC, Morgan Stanley, Morgan Stanley, ArrowMark Colorado Holdings LLC, AXA, Parametric Portfolio Associates LLC, and Blair William & Co. IL. View insider buying and selling activity for Accelerate Diagnostics.

AXDX stock was acquired by a variety of institutional investors in the last quarter, including Griffin Asset Management Inc., BNP Paribas Arbitrage SA, Two Sigma Investments LP, Baird Financial Group Inc., Raging Capital Management LLC, Oxford Financial Group Ltd., Two Sigma Advisers LP, and State Street Corp. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, John Patience, Steven Reichling, and Thomas D Brown. View insider buying and selling activity for Accelerate Diagnostics.

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AXDX stock can currently be purchased for approximately $8.25.

Accelerate Diagnostics has a market capitalization of $455.99 million and generates $9.30 million in revenue each year. The medical research company earns $-84,310,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. Accelerate Diagnostics employs 287 workers across the globe.

The official website for Accelerate Diagnostics is acceleratediagnostics.com.

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]